Equities researchers at Barrington Research raised their Q3 2025 EPS estimates for shares of H&R Block in a research report issued to clients and investors on Wednesday, February 5th. Barrington ...

Zacks Research decreased their Q1 2025 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will ...

Founded in 1978 and headquartered in Arlington, Texas, D.R. Horton, Inc. (DHI) is the largest homebuilder in the U.S. by ...

In a report released today, Tim Anderson from Bank of America Securities reiterated a Sell rating on Amgen (AMGN – Research Report), with a price target of $256.00. Tim Anderson’s rating is ...

Rapt Therapeutics (RAPT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Jefferies analyst Tycho Peterson has reiterated their bullish stance on TMO stock, giving a Buy rating today ... but earnings per share (EPS) outperforming due to significant operating margin ...

On Sept. 24, UBS Group cut its target price on the company to $125.00 from $155.00, keeping its rating at 'neutral' in a note. By contrast, DA Davidson reaffirmed a "buy" rating with a $175.00 ...

EPS of $2.61 beat estimates of $2.35 ... Home closings for the quarter numbered 19,059, slightly down from last year's 19,340. D.R. Horton topped expectations in a turbulent housing market ...

In my last report on Cathay General, I adopted a hold rating on the stock, with a December 2025 target price of $46.20. As I have reduced my EPS estimate, my target price has also declined.